[go: up one dir, main page]

MX2017014991A - Beta-caseina a2 y su capacidad antioxidante. - Google Patents

Beta-caseina a2 y su capacidad antioxidante.

Info

Publication number
MX2017014991A
MX2017014991A MX2017014991A MX2017014991A MX2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A
Authority
MX
Mexico
Prior art keywords
beta
animal
disease
antioxidant capacity
casein
Prior art date
Application number
MX2017014991A
Other languages
English (en)
Other versions
MX392728B (es
Inventor
John Clarke Andrew
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57394138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017014991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2017014991A publication Critical patent/MX2017014991A/es
Publication of MX392728B publication Critical patent/MX392728B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Mejora de la capacidad antioxidante en un animal aumentando el nivel de glutatión en la sangre o tejido del animal que comprende proporcionar una composición que contiene beta-caseína al animal para el consumo, donde la beta-caseína comprende al menos 75% en peso de una o más beta-caseínas que no pueden producir beta-casomorfina-7 en la digestión enzimática. Los usos incluyen como oxidante, para tratar o prevenir los síntomas de cáncer, inflamación, kwashiorkor (deficiencia de proteína), convulsiones, autismo, síndrome de Down, síndrome de fatiga crónica, enfermedad de Alzheimer, enfermedad de Parkinson, anemia de células falciformes, enfermedad hepática, fibrosis quística, VIH, SIDA, infección, ataque cardíaco, apoplejía y diabetes, evitando o reduciendo los efectos del envejecimiento, promoviendo la recuperación de tejido después del ejercicio físico y promoviendo la fertilidad.
MX2017014991A 2015-05-22 2016-05-20 Beta-caseina a2 y su capacidad antioxidante. MX392728B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165854P 2015-05-22 2015-05-22
PCT/NZ2016/050081 WO2016190750A1 (en) 2015-05-22 2016-05-20 Beta-casein a2 and antioxidant capacity

Publications (2)

Publication Number Publication Date
MX2017014991A true MX2017014991A (es) 2018-04-10
MX392728B MX392728B (es) 2025-03-24

Family

ID=57394138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014991A MX392728B (es) 2015-05-22 2016-05-20 Beta-caseina a2 y su capacidad antioxidante.

Country Status (17)

Country Link
US (1) US10702580B2 (es)
EP (1) EP3297643A4 (es)
JP (1) JP7137745B2 (es)
KR (1) KR102374024B1 (es)
CN (1) CN107708711A (es)
AU (2) AU2016267960B2 (es)
BR (1) BR112017024975B1 (es)
CA (1) CA2986889C (es)
CL (1) CL2017002967A1 (es)
HK (1) HK1250631A1 (es)
IL (1) IL255725B (es)
MX (1) MX392728B (es)
MY (1) MY190600A (es)
PH (1) PH12017550132A1 (es)
RU (1) RU2751945C9 (es)
WO (1) WO2016190750A1 (es)
ZA (1) ZA201707968B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7394527B2 (ja) 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
US11925197B2 (en) * 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota
CN115553340A (zh) * 2022-10-18 2023-01-03 北大荒完达山乳业股份有限公司 一种具有提高免疫力功能的降敏牛奶及其制备方法
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451368B1 (en) 1994-04-11 2002-09-17 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
DE69634831T2 (de) 1995-05-16 2006-06-29 A2 Corp. Ltd., Newmarket Nahrungsmittel und herstellungsverfahren
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
RU2280448C2 (ru) * 2002-11-10 2006-07-27 Институт биофизики клетки РАН Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих
MXPA06009529A (es) * 2004-02-23 2007-04-10 Texas A & M Univ Sys Composiciones antioxidantes y metodos para el uso de las mismas.
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
EP2448958A4 (en) * 2009-06-01 2013-11-06 Kenneth James Friel HUMAN MILK PEPTIDES
HUE050010T2 (hu) * 2012-03-09 2020-11-30 Fonterra Cooperative Group Ltd Kazein készítmények alkalmazása
WO2014194292A1 (en) * 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders
SG10201709509RA (en) * 2013-05-31 2017-12-28 A2 Milk Co Ltd Beta-Casein A2 And Prevention Of Inflammation Of The Bowel
CA3214545A1 (en) 2013-07-12 2015-01-15 The A2 Milk Company Limited Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
MX376874B (es) * 2013-08-23 2025-03-07 A2 Milk Co Ltd Beta-caseina a2 y niveles de glucosa en sangre.

Also Published As

Publication number Publication date
IL255725B (en) 2021-10-31
CL2017002967A1 (es) 2018-06-01
KR102374024B1 (ko) 2022-03-11
IL255725A (en) 2018-01-31
JP7137745B2 (ja) 2022-09-15
HK1250631A1 (zh) 2019-01-11
US20180169186A1 (en) 2018-06-21
EP3297643A1 (en) 2018-03-28
WO2016190750A1 (en) 2016-12-01
RU2017142002A3 (es) 2019-11-21
MY190600A (en) 2022-04-27
CN107708711A (zh) 2018-02-16
CA2986889C (en) 2023-08-29
BR112017024975B1 (pt) 2022-03-15
PH12017550132A1 (en) 2018-05-07
NZ737716A (en) 2024-11-29
RU2751945C2 (ru) 2021-07-21
RU2751945C9 (ru) 2021-12-21
AU2016267960B2 (en) 2022-04-07
AU2016267960A1 (en) 2017-12-14
EP3297643A4 (en) 2019-02-06
KR20180010251A (ko) 2018-01-30
ZA201707968B (en) 2019-10-30
BR112017024975A2 (pt) 2018-08-07
US10702580B2 (en) 2020-07-07
JP2018514236A (ja) 2018-06-07
RU2017142002A (ru) 2019-06-24
AU2022204759A1 (en) 2022-07-28
MX392728B (es) 2025-03-24
CA2986889A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CO2020010342A2 (es) Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas
CL2019000575A1 (es) Análogos de amilina.
MX2018006989A (es) Metodos y composiciones para el tratamiento contra un trastorno asociado a serpinc1.
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
ECSP17028310A (es) Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
BR112013017154A2 (pt) uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
PE20090064A1 (es) Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
CL2019002362A1 (es) Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas.
MX2017014991A (es) Beta-caseina a2 y su capacidad antioxidante.
PE20181047A1 (es) Suplemento alimenticio compuesto por polisacaridos vegetales
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
MX391062B (es) Composicion para corregir o prevenir higado graso no alcoholico.
MX2016005359A (es) Composicion para usarse en el tratamiento de la tos.
BR112017025189A2 (pt) composição e usos da mesma
CO2017007007A2 (es) Análogos de calcitonina
CL2018001782A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter.
MX2014013566A (es) Terapia genica para tratar la hiperamonemia en la encefalopatia hepatica y en otras enfermedades del higado.